
Presentation of the report
This report has been prepared in accordance with the Norwegian Transparency Act (the “Transparency Act”) section 5 and summarizes the policies and procedures in Nattopharma AS (“Nattopharma”) with respect to safeguarding of human rights and decent working conditions and provides information on the imolementation and results of NattoPharma’s due diligence.
View the 2022 Transparency Act Report
Latest news & videos

- MenaQ7®
- News
- Press Release
- Sep 22, 2023
New Clinical Evidence: MenaQ7® K2 Supports Normal Blood Pressure
Gnosis is thrilled to share additional evidence affirming the protective effects of vitamin K2...

- News
- Quatrefolic
- Reproduction & Women's Health
Quatrefolic® 360° collection: Active Folate and Anemia
Vitamin deficiency anemia is a lack of healthy red blood cells caused by a...

- Emothion
- Lynside®
- MenaQ7®
- Sep 15, 2023
Join us at Vitafoods Asia booth G11
Gnosis by Lesaffre will be present at Vitafoods Asia this coming 20-22 September. Join...